Literature DB >> 20019850

Respiratory syncytial virus vaccine: Is it coming?

Valérie Sales1, Elaine El Wang.   

Abstract

Respiratory syncytial virus (RSV) is recognized as an important cause of childhood morbidity and mortality. Vaccine development has been challenging in young infants and has required the advent of molecular technologies to optimize the safety profile, while maintaining immunogenicity of live-attenuated vaccines. Protein-based vaccines have been evaluated in clinical trials and are promising candidates for RSV-primed populations or for maternal vaccination to provide early life protection. This review provides a summary of the need for an RSV vaccine, as well as the challenges and progress in the vaccine's development.

Entities:  

Keywords:  Paediatrics; Prevention; Respiratory syncytial virus; Vaccine

Year:  2003        PMID： 20019850      PMCID： PMC2795278          DOI： 10.1093/pch/8.10.605

Source DB:  PubMed          Journal:  Paediatr Child Health        ISSN： 1205-7088            Impact factor:   2.253


  71 in total

1.  Respiratory syncytial virus. I. Virus recovery and other observations during 1960 outbreak of bronchiolitis, pneumonia, and minor respiratory diseases in children.

Authors:  R M CHANOCK; H W KIM; A J VARGOSKO; A DELEVA; K M JOHNSON; C CUMMING; R H PARROTT
Journal:  JAMA       Date:  1961-05-27       Impact factor: 56.272

2.  An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine.

Authors:  A Z Kapikian; R H Mitchell; R M Chanock; R A Shvedoff; C E Stewart
Journal:  Am J Epidemiol       Date:  1969-04       Impact factor: 4.897

Review 3.  Influence of maternal antibodies on neonatal immunization against respiratory viruses.

Authors:  J E Crowe
Journal:  Clin Infect Dis       Date:  2001-10-05       Impact factor: 9.079

4.  The etiology of pneumonia in malnourished and well-nourished Gambian children.

Authors:  R A Adegbola; A G Falade; B E Sam; M Aidoo; I Baldeh; D Hazlett; H Whittle; B M Greenwood; E K Mulholland
Journal:  Pediatr Infect Dis J       Date:  1994-11       Impact factor: 2.129

Review 5.  Community-acquired pneumonia.

Authors:  T J Marrie
Journal:  Clin Infect Dis       Date:  1994-04       Impact factor: 9.079

6.  Replacement of the F and G proteins of respiratory syncytial virus (RSV) subgroup A with those of subgroup B generates chimeric live attenuated RSV subgroup B vaccine candidates.

Authors:  S S Whitehead; M G Hill; C Y Firestone; M St Claire; W R Elkins; B R Murphy; P L Collins
Journal:  J Virol       Date:  1999-12       Impact factor: 5.103

7.  Immunity to and frequency of reinfection with respiratory syncytial virus.

Authors:  C B Hall; E E Walsh; C E Long; K C Schnabel
Journal:  J Infect Dis       Date:  1991-04       Impact factor: 5.226

8.  Bronchiolitis-associated mortality and estimates of respiratory syncytial virus-associated deaths among US children, 1979-1997.

Authors:  D K Shay; R C Holman; G E Roosevelt; M J Clarke; L J Anderson
Journal:  J Infect Dis       Date:  2000-11-10       Impact factor: 5.226

9.  Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity.

Authors:  S S Whitehead; C Y Firestone; R A Karron; J E Crowe; W R Elkins; P L Collins; B R Murphy
Journal:  J Virol       Date:  1999-02       Impact factor: 5.103

10.  Respiratory syncytial virus or influenza?

Authors:  D M Fleming; K W Cross
Journal:  Lancet       Date:  1993 Dec 18-25       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.